KPTI Strangle Strategy
KPTI (Karyopharm Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus.
KPTI (Karyopharm Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $46.0M, a beta of 0.95 versus the broader market, a 52-week range of 1.8-10.99, average daily share volume of 923K, a public-listing history dating back to 2013, approximately 228 full-time employees. These structural characteristics shape how KPTI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.95 places KPTI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on KPTI?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
KPTI snapshot
As of August 14, 2026, spot at $2.00, ATM IV 182.90%, IV rank 34.26%, expected move 52.44%. The strangle on KPTI below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on KPTI specifically: KPTI IV at 182.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 52.44% (roughly $1.05 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KPTI expiries trade a higher absolute premium for lower per-day decay. Position sizing on KPTI should anchor to the underlying notional of $2.00 per share and to the trader's directional view on KPTI stock.
KPTI strangle setup
The KPTI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KPTI at $2.00 on that close, the first option leg uses a $2.10 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KPTI chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KPTI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.10 | N/A |
| Buy 1 | Put | $1.90 | N/A |
KPTI strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
KPTI strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on KPTI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on KPTI
Strangles on KPTI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KPTI chain.
KPTI thesis for this strangle
The market-implied 1-standard-deviation range for KPTI extends from approximately $0.95 on the downside to $3.05 on the upside. A KPTI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current KPTI IV rank near 34.26% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on KPTI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, KPTI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KPTI-specific events.
KPTI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KPTI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KPTI alongside the broader basket even when KPTI-specific fundamentals are unchanged. Always rebuild the position from current KPTI chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on KPTI?
- A strangle on KPTI is the strangle strategy applied to KPTI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With KPTI stock at $2.00 on the most recent close, the strikes shown on this page are snapped to the nearest listed KPTI chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are KPTI strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the KPTI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 182.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KPTI strangle?
- The breakeven for the KPTI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The KPTI market-implied 1-standard-deviation expected move in the same options snapshot is approximately 52.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on KPTI?
- Strangles on KPTI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KPTI chain.
- How does current KPTI implied volatility affect this strangle?
- KPTI ATM IV is at 182.90% with IV rank near 34.26%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.